- Home
- UBS vs GILD Comparison
UBS vs GILD Comparison
Compare UBS & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | GILD |
|---|---|---|
| Founded | 1862 | 1987 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1B | 168.6B |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | UBS | GILD |
|---|---|---|
| Price | $48.97 | $125.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 18 |
| Target Price | $60.30 | ★ $148.39 |
| AVG Volume (30 Days) | 2.2M | ★ 6.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 1.29% | ★ 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $7.40 | $4.68 |
| Revenue Next Year | $2.83 | $6.04 |
| P/E Ratio | ★ $17.22 | $78.17 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $30.39 | $107.19 |
| 52 Week High | $49.36 | $157.29 |
Technical Indicators
Market Signals| Indicator | UBS | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 40.15 |
| Support Level | $46.47 | $116.55 |
| Resistance Level | $49.36 | $126.46 |
| Average True Range (ATR) | 0.80 | 3.58 |
| MACD | -0.08 | -0.57 |
| Stochastic Oscillator | 97.82 | 25.87 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).